Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Rating of “Hold” from Analysts

Orthofix Medical Inc. (NASDAQ:OFIX) has been given an average recommendation of “Hold” by the seven ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $20.00.

Several research analysts have recently weighed in on OFIX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Orthofix Medical in a research note on Thursday, January 22nd. Barrington Research upped their price objective on shares of Orthofix Medical from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Stifel Nicolaus began coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, TD Cowen started coverage on shares of Orthofix Medical in a research note on Tuesday, January 27th. They set a “hold” rating and a $14.00 target price for the company.

Orthofix Medical Price Performance

Shares of Orthofix Medical stock opened at $13.45 on Tuesday. The firm has a market cap of $532.62 million, a PE ratio of -4.44 and a beta of 0.79. Orthofix Medical has a twelve month low of $10.24 and a twelve month high of $20.48. The company has a quick ratio of 1.38, a current ratio of 2.47 and a debt-to-equity ratio of 0.39. The business has a 50-day moving average price of $15.03 and a 200 day moving average price of $14.51.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, CFO Julie Andrews sold 4,873 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $14.38, for a total transaction of $70,073.74. Following the completion of the transaction, the chief financial officer owned 58,039 shares of the company’s stock, valued at $834,600.82. This represents a 7.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Massimo Calafiore sold 9,797 shares of Orthofix Medical stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $15.21, for a total value of $149,012.37. Following the completion of the sale, the chief executive officer directly owned 217,237 shares in the company, valued at $3,304,174.77. This represents a 4.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 24,270 shares of company stock valued at $370,958. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Orthofix Medical

A number of large investors have recently modified their holdings of OFIX. Paradigm Capital Management Inc. NY grew its position in shares of Orthofix Medical by 34.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company’s stock valued at $37,248,000 after purchasing an additional 858,900 shares in the last quarter. Millennium Management LLC boosted its stake in Orthofix Medical by 86.6% during the third quarter. Millennium Management LLC now owns 1,475,718 shares of the medical device company’s stock worth $21,605,000 after buying an additional 684,850 shares during the last quarter. Bank of America Corp DE boosted its stake in Orthofix Medical by 659.5% during the second quarter. Bank of America Corp DE now owns 687,410 shares of the medical device company’s stock worth $7,665,000 after buying an additional 596,907 shares during the last quarter. Engine Capital Management LP grew its holdings in Orthofix Medical by 13.6% in the 2nd quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock valued at $47,406,000 after buying an additional 510,281 shares in the last quarter. Finally, AYAL Capital Advisors Ltd increased its stake in shares of Orthofix Medical by 74.7% in the 2nd quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock worth $10,517,000 after acquiring an additional 403,433 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.